| Name | Title | Contact Details |
|---|
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
MedShift, founded in 2015 in Charlotte, NC delivers platform as a service to both medical device manufacturers as well as individual medical practices. Foundationally MedShift enables access to the latest devices and technology to remain competitive and attract new business. MedShift has partnered with over 250 providers in North America, Australia, and New Zealand to give practices the latest in cutting-edge treatment modalities, services, and systems. MedShift is disrupting the traditional aesthetic device market by offering permanent placement, holistic subscription services for surgeons, physicians and their business. MedShift`s broad portfolio of services for practices includes a portfolio of 24 leading aesthetic medical devices from six manufacturers, an aesthetic eCommerce and subscription platform, in-house communications and marketing services, and inbound lead generation. For manufacturers MedShift delivers a highly secure IoT platform consisting of both hardware and software assets allowing for real time visibility, remote management, and big data modeling of entire medical device lineups. MedShift adds value across manufacturer and provider spectrum and continues to empower robust integration with leading brands and doctors in the industry.
Wasatch Microfluidics is a North Salt Lake, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fullpower is the leader for cloud-based IoT smart-home and wearable solutions powered by AI, machine-learning and data science. With more than 125 patents, the Fullpower IP portfolio covers the AI-powered Sleeptracker® and the MotionX® IoT technology platforms for the Smart-Home and wearable. Fullpower`s business model is to license technology and IP to brand leaders such as Nike, BeautyRest, Amazon, Movado, Serta and others. Founded by Philippe Kahn, creator of the first camera-phone and based in Silicon Valley, the Fullpower team is passionate about technology craftsmanship, innovation, and the global AI-IoT paradigm shift.